You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

VEGF; pmCNV; antibody

Showing 1 - 25 of 6,901
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

Not yet recruiting
  • Lung Adenocarcinoma
  • +3 more
  • Serplulimab and Bevacizumab injection
  • (no location specified)
Dec 21, 2022

SCLC, Extensive Stage Trial in Shanghai (AK112, Etoposide, Carboplatin)

Recruiting
  • SCLC, Extensive Stage
  • Shanghai, Shanghai, China
    Shun Lu
Oct 12, 2022

Malignant Tumor Trial in Shanghai (PM8002)

Recruiting
  • Malignant Neoplasm
  • Shanghai, Shanghai, China
    Shanghai Orient Hospital
Jun 25, 2023

Pathological Myopic Choroidal Neovascularization Trial in BeiJing (601, Ranibizumab)

Recruiting
  • Pathological Myopic Choroidal Neovascularization
  • BeiJing, China
    Peking Union Medical College Hospital
Jun 4, 2021

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • HAIC
  • +8 more
  • Quanzhou, Fujian, China
  • +1 more
Jan 26, 2023

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE
  • +8 more
  • Quanzhou, Fujian, China
  • +3 more
Jan 29, 2023

Advanced Malignant Tumors Trial in Hangzhou (AK112, AK117, Carboplatin)

Recruiting
  • Advanced Malignant Tumors
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 10, 2022

Solid Tumor, Adult Trial in Guangzhou (AK112)

Active, not recruiting
  • Solid Tumor, Adult
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 8, 2022

Advanced Cancer Trial in Houston (Dasatinib, Bevacizumab, Paclitaxel)

Completed
  • Advanced Cancer
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Nov 21, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Tumors Malignant Trial in Shanghai (B1962)

Not yet recruiting
  • Neoplasms Malignant
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Dec 13, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Ovarian Tumors, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer Trial in Beijing (AK112 low dose, AK112 medium dose, AK112

Terminated
  • Ovarian Neoplasms
  • +3 more
  • AK112 low dose
  • +2 more
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Oct 8, 2022

Recurrent Brain Tumor Trial in Houston (biological, other, radiation)

Active, not recruiting
  • Recurrent Brain Neoplasm
  • Bevacizumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,

Not yet recruiting
  • Metastatic Colorectal Carcinoma
  • +3 more
  • Bevacizumab
  • +11 more
  • (no location specified)
May 9, 2023

Advanced Malignant Tumors Trial in Hangzhou (AK112, AK117, Chemotherapy)

Recruiting
  • Advanced Malignant Tumors
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Jan 27, 2022

Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial

Recruiting
  • Resectable Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab
  • +2 more
  • Houston, Texas
  • +1 more
Oct 12, 2022

Ovarian Cancer Trial in Houston (Pembrolizumab, Bevacizumab, Cyclophosphamide)

Not yet recruiting
  • Ovarian Cancer
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

Ovarian Cancer Trial in Houston (Paclitaxel, Bevacizumab, Lurbinectedin)

Not yet recruiting
  • Ovarian Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Nov 23, 2022

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +5 more
  • Bevacizumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 13, 2022

Tumors Malignant Trial in Australia (AK112)

Recruiting
  • Neoplasms Malignant
  • Albury, New South Wales, Australia
  • +6 more
Oct 26, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 29, 2022

Liver Cancer Trial in Houston (Bevacizumab, Atezolizumab, Sofosbuvir)

Not yet recruiting
  • Liver Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Feb 9, 2023

Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma Trial in Los Angeles, San Diego (biological, drug, other, genetic)

Active, not recruiting
  • Giant Cell Glioblastoma
  • +2 more
  • bevacizumab
  • +5 more
  • Los Angeles, California
  • +2 more
Feb 10, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Bevacizumab
  • +4 more
  • Phoenix, Arizona
  • +2 more
Jun 27, 2022